Gain Therapeutics, Inc. received approval for dosing extension in Australia, and Gene Mack was appointed President and CEO.
3 reports, 1 independent
Updated Sep 4
Gone quiet
- Reports
- 3
- Developments
- 3
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Gain Therapeutics, Inc. received approval for dosing extension in Australia, and Gene Mack was appointed President and CEO.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Australian dosing extension approval for Gain Therapeutics; Gene Mack appointed President and CEO.1 source
Gain deploys Magellan platform and management presents at BTIG conference.1 source
- Gain Therapeutics extended the screening window for its study in Australia.
Keep exploring
The entities involved
-
Gene Mack
actor
Nothing else this week.
Coverage
Newest first; wire copies grouped- GlobeNewswireGain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation Ongoing Phase 1b trial of GT-02287 to be extended
- GlobeNewswireGain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference BETHESDA, Md., July 24, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clin
- Unknown outlet